SLU-PP-332
ERR Agonist — Exercise Mimetic
Dosage
5mg
Unit Size
1 Vial
// Add to Cart
5mg
$100.00
28 in stock
What is SLU-PP-332?
SLU-PP-332 is a small-molecule compound developed at Washington University in St. Louis that simultaneously activates all three estrogen-related receptors (ERRα, ERRβ, and ERRγ). Often called an "exercise mimetic," it activates the same gene expression pathways engaged during sustained aerobic exercise — without requiring physical activity. Preclinical studies showed up to 70% improvements in run time in treated subjects.
3
ERR Receptors Activated
~70%
Run Time Increase (Preclinical)
Oral/SQ
Administration Route
Key Benefits
Endurance Enhancement
Dramatically improves aerobic endurance capacity in preclinical models without changes in training volume.
Fat Oxidation
Upregulates fatty acid oxidation pathways, shifting the body toward fat as a primary fuel source.
Mitochondrial Biogenesis
Stimulates the production of new mitochondria, increasing cellular energy capacity and metabolic efficiency.
Metabolic Flexibility
Promotes the ability to efficiently switch between glucose and fat as fuel sources — a hallmark of metabolic health.
Muscle Protection
Investigated for potential to protect against obesity-induced muscle wasting and age-related metabolic dysfunction.
Cardiac & Skeletal Benefits
ERR activation supports mitochondrial health in both cardiac and skeletal muscle — two of the body's highest energy-demand tissues.
How It Works
ERR Receptor Binding
SLU-PP-332 directly binds to and activates ERRα, ERRβ, and ERRγ — orphan nuclear receptors that regulate mitochondrial energy metabolism.
Mitochondrial Gene Upregulation
ERR activation drives expression of genes involved in oxidative phosphorylation, electron transport, and mitochondrial biogenesis — the same genes activated by aerobic exercise.
Fatty Acid Oxidation Program
Activates the PGC-1α co-activator network and downstream fatty acid oxidation enzymes, enabling greater fat utilization at rest and during activity.
Metabolic Reprogramming
By activating all three ERR subtypes simultaneously, SLU-PP-332 induces a comprehensive "exercise-like" metabolic reprogramming of target tissues.
Common Protocol (Research Reference)
5 mg
Dose per injection
5×/week
Frequency
4–8 wks
Typical cycle length
Research Use Notice
SLU-PP-332 is a research peptide not approved by the FDA for human use. This information is for educational purposes only. Always consult a qualified healthcare professional before considering any peptide protocol.